Tags

Type your tag names separated by a space and hit enter

[Kidney function in hypertensive patients with chronic renal failure treated with the dual eliminated ACE-inhibitor spirapril].
Med Klin (Munich). 1994 Aug 15; 89(8):416-20.MK

Abstract

PATIENTS AND METHOD

Spirapril is a recent ACE inhibitor with a both renal and hepatic elimination pathway. In order to determine its tolerability, primarily the impact on renal function, Spirapril was tested in a single-blind trial with a 2-week placebo run-in phase and a 4-week active treatment period. Forty-nine patients (34 males and 15 females) with varying degrees of renal impairment were included. Their pretreatment diastolic blood pressure (DBP) ranged from 95 to 115 mm Hg. Spirapril was administered in oral doses of 6 mg once daily.

RESULTS

Forty-four patients completed the study. Four patients dropped out due to side effects, 1 patient was withdrawn from the study due to lack of antihypertensive efficacy. 48% of the completers with renal failure achieved a normalized diastolic blood pressure (DBP < or = 90 mm Hg) or a reduction in DBP of > or = 10 mm Hg; the corresponding figure for patients with normal renal function was 31%. Renal function was assessed in the beginning and at the end of the active Spirapril treatment period using Tc-99m-DTPA-clearance (representing glomerular filtration rate), J-131-hippuran-clearance (representing renal plasma flow) and creatinine clearance. Particularly in patients with renal impairment, Spirapril did not deteriorate renal function as given by these parameters. Regression analysis revealed a linear correlation between total plasma clearance of the active metabolite Spiraprilate and creatinine clearance. There was no evidence for drug accumulation.

CONCLUSION

In patients with renal impairment the pharmacokinetic results indicate a non-renal elimination of the drug. Spirapril 6 mg once daily is concluded to be a well tolerated antihypertensive therapy for patients with mild to moderate hypertension and varying degrees of chronic renal failure.

Authors+Show Affiliations

Klinik für Innere Medizin IV am Klinikum der Friedrich-Schiller-Universität Jena.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Case Reports
Clinical Trial
Controlled Clinical Trial
English Abstract
Journal Article
Multicenter Study

Language

ger

PubMed ID

7968874

Citation

Haufe, C C., et al. "[Kidney Function in Hypertensive Patients With Chronic Renal Failure Treated With the Dual Eliminated ACE-inhibitor Spirapril]." Medizinische Klinik (Munich, Germany : 1983), vol. 89, no. 8, 1994, pp. 416-20.
Haufe CC, Sierakowski B, Jansa U, et al. [Kidney function in hypertensive patients with chronic renal failure treated with the dual eliminated ACE-inhibitor spirapril]. Med Klin (Munich). 1994;89(8):416-20.
Haufe, C. C., Sierakowski, B., Jansa, U., & Stein, G. (1994). [Kidney function in hypertensive patients with chronic renal failure treated with the dual eliminated ACE-inhibitor spirapril]. Medizinische Klinik (Munich, Germany : 1983), 89(8), 416-20.
Haufe CC, et al. [Kidney Function in Hypertensive Patients With Chronic Renal Failure Treated With the Dual Eliminated ACE-inhibitor Spirapril]. Med Klin (Munich). 1994 Aug 15;89(8):416-20. PubMed PMID: 7968874.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Kidney function in hypertensive patients with chronic renal failure treated with the dual eliminated ACE-inhibitor spirapril]. AU - Haufe,C C, AU - Sierakowski,B, AU - Jansa,U, AU - Stein,G, PY - 1994/8/15/pubmed PY - 2000/3/22/medline PY - 1994/8/15/entrez SP - 416 EP - 20 JF - Medizinische Klinik (Munich, Germany : 1983) JO - Med Klin (Munich) VL - 89 IS - 8 N2 - PATIENTS AND METHOD: Spirapril is a recent ACE inhibitor with a both renal and hepatic elimination pathway. In order to determine its tolerability, primarily the impact on renal function, Spirapril was tested in a single-blind trial with a 2-week placebo run-in phase and a 4-week active treatment period. Forty-nine patients (34 males and 15 females) with varying degrees of renal impairment were included. Their pretreatment diastolic blood pressure (DBP) ranged from 95 to 115 mm Hg. Spirapril was administered in oral doses of 6 mg once daily. RESULTS: Forty-four patients completed the study. Four patients dropped out due to side effects, 1 patient was withdrawn from the study due to lack of antihypertensive efficacy. 48% of the completers with renal failure achieved a normalized diastolic blood pressure (DBP < or = 90 mm Hg) or a reduction in DBP of > or = 10 mm Hg; the corresponding figure for patients with normal renal function was 31%. Renal function was assessed in the beginning and at the end of the active Spirapril treatment period using Tc-99m-DTPA-clearance (representing glomerular filtration rate), J-131-hippuran-clearance (representing renal plasma flow) and creatinine clearance. Particularly in patients with renal impairment, Spirapril did not deteriorate renal function as given by these parameters. Regression analysis revealed a linear correlation between total plasma clearance of the active metabolite Spiraprilate and creatinine clearance. There was no evidence for drug accumulation. CONCLUSION: In patients with renal impairment the pharmacokinetic results indicate a non-renal elimination of the drug. Spirapril 6 mg once daily is concluded to be a well tolerated antihypertensive therapy for patients with mild to moderate hypertension and varying degrees of chronic renal failure. SN - 0723-5003 UR - https://www.unboundmedicine.com/medline/citation/7968874/[Kidney_function_in_hypertensive_patients_with_chronic_renal_failure_treated_with_the_dual_eliminated_ACE_inhibitor_spirapril]_ DB - PRIME DP - Unbound Medicine ER -